Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Oral Communications

Oral Communications 9: Endocrine-Related Cancer

ea0073oc9.1 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Thymic neuroendocrine tumor and mortality in MEN 1 patients: the spanish registry

Casteras Anna , Valdés Nuria , Lamas Cristina , Gaztambide Sonia , Paja Fano Miguel , Navarro Elena , Álvarez Escol Cristina , Diego Estrella , Calatayud María , Segura Pedro , Oriola Josep , Spanish group for the study of MEN and PPGL

BackgroundThymic neuroendocrine tumor (THY-NET) accounts for almost 20% of multiple endocrine neoplasia type 1 (MEN1)-associated mortality. Diagnosis at early tumor stage is associated with improved survival.ObjectiveTo study the prevalence, clinical features and prognosis of THY-NET in MEN 1. To describe the overall causes of death among the registered MEN1 patients. To compare and discuss our results with t...

ea0073oc9.2 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Utility of In1-ghrelin as a novel non-invasive diagnostic and prognostic biomarker of prostate cancer in patients with PSA in the grey-zone

Montero-Hidalgo Antonio J. , Herrero-Aguayo Antonio J. , Enrique Gómez-Gómez , Guler Ipek , Justo P. Castaño , Sarmento-Cabral André , Gahete Ortiz Manuel , Luque Raul M , Jiménez Vacas Juan Manuel

Prostate cancer (PCa) is one of the leading causes of cancer deaths among men population worldwide. This tumour pathology is commonly diagnosed through the determination of serum PSA levels. However, the diagnostic capability of PSA dramatically drops when considering patients with PSA levels lower than 10 ng/ml, the so-called “grey-zone”1. Therefore, additional non-invasive diagnostic biomarkers are urgently needed to substitute/complement PSA. In this se...

ea0073oc9.3 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Dysregulation of alternative splicing unveils new avenues for targeting pulmonary carcinoids

Blázquez-Encinas Ricardo , Teresa Caro María , García-Vioque Víctor , Pedraza-Arévalo Sergio , Alors-Pérez Emilia , Dulcínea Herrera-Martínez Aura , Sánchez-Sánchez Rafael , Serrano-Blanch Raquel , Foll Matthieu , Fernández-Cuesta Lynnette , D Gahete Manuel , M Luque Raúl , Ibáñez-Costa Alejandro , P Castaño Justo

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...

ea0073oc9.4 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Splicing machinery landscape is dysregulated in chronic liver disease: central role of EIF4A3 in hepatocarcinogenesis.

López-Cánovas Juan Luis , Hermán-Sánchez Natalia , Moreno-Montilla María T , del Rio-Moreno Mercedes , Sánchez-Frias Marina E. , Amado Víctor , Ciria Rubén , Briceño Javier , de la Mata Manuel , Castaño Justo P. , Rodriguez-Perálvarez Manuel , Luque Raul M , Gahete Ortiz Manuel

Endocrine-metabolic alterations such as obesity and metabolic syndrome are closely linked to the development of chronic liver diseases, from metabolic-associated fatty liver (MAFLD) to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). An emerging hallmark of endocrine-metabolic and hepatic diseases is the appearance or altered expression of pathological splicing variants (SVs). In fact, the components of the cellular machinery involved in the splicing pr...

ea0073oc9.5 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Reassessment of the diagnostic criteria of insulinoma: A retrospective monocentric cohort study of 72-h fasting trial in 124 patients

Fideline Bonnet , Devingenteuil Clara , Vaczlavik Anna , Bessiene Laura , Laguillier-Morizot Christelle , Assié Guillaume , Helen Mosnier-Pudar , Terris Benoît , Groussin Lionel , Guibourdenche Jean , Bertherat Jerome

IntroductionFasting trial remains the gold standard to confirm the diagnosis of insulinoma, based on low blood glucose level concomitant with inadequate high insulin level. However, diagnostic criteria are not consensual. Glycemia and insulin thresholds differ between the different consensus statements : endogenous hyperinsulism diagnosis relies on a glycemia < 3 mmol/l associated with an insulin level > 3 mUI/l in Endocrine Society guidelines (2009)...

ea0073oc9.6 | Oral Communications 9: Endocrine-Related Cancer | ECE2021

Presence and pathophysiological role of sst5TMD4, an aberrant spliced variant of the somatostatin receptor subtype 5, in human high-grade astrocytomas

Garcia Garcia Miguel , Fuentes-Fayos Antonio C. , Blanco-Acevedo Cristobal , Solivera Juan , Gahete Ortiz Manuel , Castaño Justo P. , Luque Raul M.

Gliomas are derived from glial-cells and are the most common primary brain tumor, characterized by rapid growth and invasion. Astrocytomas are a subset of malignant gliomas which are classified, based on their agresiveness features, in low grades (I and II) to high grades (HGAs; III and IV), being grade-IV (glioblastoma multiforme; GBM) the most malignant and aggressive type. Current standard treatment for GBMs consists on surgery followed by radiotherapy/chemotherapy; however...